oMeds
All answers
Answer · metabolic

Is tirzepatide better than semaglutide?

Short answer

Head-to-head trials show tirzepatide drives larger average weight loss and greater A1C reduction than semaglutide. Tirzepatide is a dual GIP/GLP-1 agonist; semaglutide is a GLP-1 mono-agonist. 'Better' depends on candidacy, tolerance, insurance access, cardiovascular history, and the targeted endpoint — it is a provider-reviewed match, not a universal winner.

Reviewed by Dr. Laura PurdyMay 29, 2026

Full answer

Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist. The SURMOUNT and SURPASS programs and head-to-head metabolic data show tirzepatide producing larger mean weight loss and larger A1C reductions at maximum tolerated dose. That does not make it the right molecule for every patient. Tolerance — particularly GI side effects during titration — differs between patients and between molecules; cardiovascular indications (semaglutide has CV outcome data in defined populations), kidney function, prior GLP-1 exposure, insurance access, and lean-mass defense strategy all shape the match. The clinically honest framing is that tirzepatide currently produces the larger average metabolic effect, while semaglutide remains a well-supported choice with the longer outcome track record. The match is provider-reviewed against the patient's biomarkers, history, and goals.

Educational. Not a substitute for individualized provider review.

References & sources

Go deeper

Related answers

Does semaglutide cause muscle loss?
GLP-1 therapy drives weight loss that includes both fat and lean mass — typically ~25–40% of total weight lost is lean tissue when no countermeasures are applied. Lean-mass loss is largely preventable with adequate protein intake, resistance training, and provider-reviewed titration; it is a protocol issue, not an inevitability of the molecule.
Metabolic syndrome criteria?
Metabolic syndrome is a cluster of five cardiometabolic markers — central adiposity, elevated triglycerides, low HDL, elevated blood pressure, and elevated fasting glucose. Diagnosis typically requires three of the five. It is an insulin-resistance-driven state that materially raises cardiovascular and type-2 diabetes risk and is reversible with provider-reviewed metabolic optimization.
What is insulin resistance?
Insulin resistance is a state where cells respond poorly to insulin, so the pancreas secretes more insulin to maintain normal blood glucose. It precedes type-2 diabetes by years and shows up first in fasting insulin, HOMA-IR, triglyceride/HDL ratio, and ApoB before A1C or fasting glucose drift. It is reversible.
Primary source
GLP-1 Standard Library